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Innate lymphoid cells (ILCs) are largely tissue resident and respond rapidly toward the
environmental signals from surrounding tissues and other immune cells. The pleiotropic
function of ILCs in diverse contexts underpins its importance in the innate arm of immune
system in human health and disease. ILCs derive from common lymphoid progenitors but
lack adaptive antigen receptors and functionally act as the innate counterpart to T-cell
subsets. The classification of different subtypes is based on their distinct transcription
factor requirement for development as well as signature cytokines that they produce.
The discovery and subsequent characterization of ILCs over the past decade have
mainly focused on the regulation of inflammation, tissue remodeling, and homeostasis,
whereas the understanding of the multiple roles and mechanisms of ILCs in cancer is
still limited. Emerging evidence of the potent immunomodulatory properties of ILCs in
early host defense signifies a major advance in the use of ILCs as promising targets
in cancer immunotherapy. In this review, we will decipher the non-exclusive roles of
ILCs associated with both protumor and antitumor activities. We will also dissect the
heterogeneity, plasticity, genetic evidence, and dysregulation in different cancer contexts,
providing a comprehensive understanding of the complexity and diversity. These will have
implications for the therapeutic targeting in cancer.
Keywords: ILCs, cancer, tumor immune microenvironment, immunosurveillance, heterogenity, plasticicity,
immunothearpy
INTRODUCTION
Innate lymphoid cells (ILCs) derive from common lymphoid progenitors (CLPs) (1, 2) and are
regulated by multiple endogenous signals including neuropeptides, hormones, cytokines and other
alarmins (3). Tissue-resident ILCs represent a heterogeneous group of cells that interact with a wide
variety of hematopoietic and non-hematopoietic cells through direct or indirect communication.
These ILCs act as functional effectors contributing to the integration of innate and adaptive
immune responses and the orchestration of physiological and pathological processes throughout
the body (1). ILCs are considered to be counterparts of T-cell subsets resembling both their
phenotypical and functional characteristics. Five subgroups of ILCs have been classified as natural
killer (NK) cells and helper-like ILCs (ILC1s, ILC2s, and ILC3s) and lymphoid tissue inducer
(LTi) cells in terms of their lineage-determining transcription factors and cytokine secretion
profiles according to a redefined nomenclature (4) (Figure 1). NK cells derive from NK-cell
precursors (NKP), which directly differentiate from common innate lymphoid progenitors (CILPs),
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whereas other ILCs derive from common helper innate lymphoid
progenitors (CHILPs) (2, 5–7). CHILP can differentiate to ILC
precursors (ILCPs) and LTi precursors (LTiPs) that give rise to
all ILC subsets (ILC1, ILC2, and ILC3) and LTis, respectively
(4, 8). The transcriptional repressor, inhibitor of DNA binding 2
(Id2), is sequentially expressed in the ILC lineage framework, and
Id2-dependent precursors can further differentiate with lineage-
specific transcription factors (9). Data from both humans and
mice demonstrate that LTi cells and conventional NK (cNK) cells
are developmentally related yet represent distinct lineages (10–
12). Recent studies reveal the previously unappreciated ILCP
heterogeneity by using polychromic reporter mice to identify
the ILCP lineage. The results suggest that a fraction of CHILP
highly expresses PLZF (Zbtb16) and PD-1 and retains potential
for all CD127hiILCs but not LTis. In addition, these cells can also
generate NK cells that express Eomes and perforin, indicating
additional lineage potential (13, 14). Likewise, an analysis of
Id2 and PLZF reporter mice reveals that Id2+Zbtb16+ILCPs
define multipotent NK and/or ILCPs and are associated with
loss of LTi potential at a clonal level, suggesting a revised model
for ILC differentiation that redefines the cell-fate potential of
helper-ILC-restricted Zbtb16+ILCPs (15) (Figure 1).
NK cells and ILC1s share the same transcription factor
T-bet and produce type 1 cytokines, including interferon-
gamma (IFNγ) and the tumor necrosis factor-alpha (TNFα),
in response to interleukin (IL)-12 and IL-18, whereas NK cells
also require the transcription factor eomesodermin (Eomes) and
produce cytotoxic proteins, perforin, and granzymes in mice and
granulysin in humans (16). NK cells and ILC1s are functionally
analogous to cytotoxic CD8+ T cells and CD4+ T helper1 (Th1)
cells, respectively. ILC2s depend onGATA3 and produce IL-4, IL-
5, IL-9, IL-13 (17, 18), and amphiregulin (AREG) (19) in response
to IL-25, IL-33, and thymic stromal lymphopoietin (TSLP), which
resembles the Th2 cells response (4). ILC3s are heterogeneous
but consistently require transcription factor RORγt for their
development and function. LTis are related to ILC3s with distinct
functions in the secondary lymphoid organ formation during
both embryonic and adult stages of development (8, 11, 20).
In general, these cells found in adult mice are termed LTi-
like cells, which have a similar phenotype to LTis (21). Both
ILC3s and LTis are capable of producing IL-17, IL-22 and
granulocyte-macrophage colony-stimulating factor (GM-CSF) in
response to IL-23, IL-1β, or natural cytotoxicity receptor ligands
(NCR-L) that reflect Th17 response (3, 22). Regardless of the
functional association with ILC3s, LTis are considered a separate
ILC lineage. Fetal liver-derived LTiPs express α4β7 integrin
and C-C Motif Chemokine Receptor 6 (CCR6), whereas adult
LTis derived from bone marrow precursors display upregulated
RORγt in a Notch-dependent manner (9, 20). Adult mice
also have T-bet-expressing CCR6−NKp46+ILC3s derived from
CCR6−NKp46−ILC3s (23) (Figure 1).
In contrast to the polarized T-cell subsets that take over
several days for activation and clonal expansion, most ILCs
can produce significant amounts of cytokines upon stimulation
without further differentiation. Hence, ILCs are considered to be
the first line of defense to confront and sense the changes in the
local environment and then react rapidly as the host response
in peripheral tissue (24). Dysregulation of ILCs manifested by
the changes in cell numbers or subset proportions is associated
with diverse inflammatory diseases and cancer (25–28). The
role of ILCs in cancer is ambivalent based on both protumor
and antitumorigenic activities depending on their phenotype,
the variety of cancer, and the tumor microenvironment
(TME) context. The remarkable heterogeneity, distinct signature
cytokines they produce, the various surface markers they express,
and the plasticity among all the different subsets make ILC
functions divergent and less comprehensible.
Given that the role of NK cells in cancer has been extensively
reviewed (29, 30), this review will mainly focus on helper-like
ILCs (ILC1s, ILC2s, and ILC3s) and LTis in the context of cancer.
The plasticity of ILCs and their interactions with the extracellular
matrix (ECM) and adaptive immune cells shape the TME. In
return, changes in the secretion of cytokines by these cells also
polarize ILC functions and influence plasticity under pathological
conditions in the TME. These bidirectional interactions are
crucial for controlling tumor growth and metastasis. Untangling
the pleotropic roles and bidirectional regulations of ILCs in
cancer will ultimately help to provide a rationale for the design
of therapeutic strategies for cancer treatment.
INNATE LYMPHOID CELLS AND TUMOR
IMMUNE MICROENVIRONMENTS
Tumor-infiltrating leukocytes were first discovered in the 1800s,
suggesting a functional relationship between immune cells
and cancer (31). These infiltrating immune cells had been
considered to have antitumor properties only until the last three
decades, when the adverse role of promoting tumor progression
has come into light. Tumor development and progression
are profoundly influenced by a variety of resident host cells,
stromal cells, the ECM, the blood and lymphatic vascular
networks, infiltrating immune cells, and signaling molecules
including growth factors, cytokines, and chemokines, collectively
known as the TME (32–35). Recognizing the importance of
the TME in cancer has revolutionized cancer treatment from
targeting tumor cells to deciphering the tumor ecosystem
complexity. This fundamentally determines the fate of the
primary tumors whether it is eradicated or a premetastatic
niche is established that favors metastatic dissemination (36, 37).
Substantial immune cell infiltration varying in size, composition
and distribution is a distinct characteristic present in almost
all types of malignant tumors. These infiltrating immune cells,
including tumor-associated macrophages (TAMs), mast cells, T
cells and ILCs within the TME, comprise the tumor immune
microenvironment (TIME) (26, 38–43).
Each of these immune components is believed to be involved
in tumorigenesis, tumor invasion, and metastasis (44, 45). From
immunosurveillance to tumor escape, infiltrating immune cells
mutually interact with other cells within the TME niche and
play a dual role that can either promote or attenuate malignant
outgrowths. Given that tumor-induced immunological changes
affect metastatic progression even before disseminated tumor
cells reach secondary organs (38), targeting the premetastatic
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FIGURE 1 | Innate lymphoid cell lineage and classification. Innate lymphoid cells (ILCs) derive from common lymphoid progenitors (CLPs) and give rise to common
innate lymphoid progenitors (CILPs) and common helper innate lymphoid progenitors (CHILPs). CILPs differentiate into natural killer (NK) cell progenitors (NKPs) and
then terminally differentiate into NK cells. CHILPs divide into innate lymphoid cell progenitors (ILCPs) and lymphoid tissue inducer progenitors (LTiPs), which generate
all helper-like ILC subsets, ILC1s, ILC2s, ILC3s, and LTis, respectively. The transcriptional repressor Id2 is developmentally required and sequentially expressed in the
ILC precursors. Id2-dependent precursors can further differentiate with lineage-specific transcription factors. Recent studies suggest that Zbtb16+ ILCPs harbored
extensive NK and/or ILC precursors potential, indicating a revised model for ILC differentiation. The different ILC subsets need their unique transcription factors for
development and secretion of their signature cytokines in response to different stimulators, which mirror the phenotype and the function of adaptive helper T cells,
Th1, Th2, and Th17, respectively.
TIME is believed to be critical for the success of therapeutic
strategies (40, 42, 46).
ILCs are tissue-resident cells in lymphoid and non-lymphoid
organs and functionally act as sentinels to maintain and
shape tissue microenvironment. They respond rapidly to
environmental changes by secreting significant amounts
of cytokines and expanding locally under physiologic and
pathological conditions, suggesting a role for these cells
in the early phases of tumorigenesis and in shaping the
TME (46).
ILCs in Extracellular Matrix Remodeling
ECM is a major component of the local TME, and its
remodeling plays a prominent role in tumor development.
ECM dysregulation promotes cancer cell invasion, induces
angiogenesis and facilitates immune cell infiltration (47).
Activated immune cells including ILCs closely interact with
ECM, which may decisively affect the outcome of tumor
progression (42).
Among the ILC family members, NK cells were first identified
as being involved in the remodeling of the tumor ECM. NKp46-
mediated IFNγ secretion increases the expression of fibronectin
1 (FN1) by tumor cells leading to ECM structural changes in
the primary tumors and decreased metastasis (48). Reciprocally,
FN1 stabilizes NK cell survival and facilitates NK cell migration
by inducing anti-apoptotic protein B-cell leukemia 2 (Bcl-2)
(49). These data suggest a bidirectional regulation between NK
cells and ECM remodeling. IL-12-responding ILC1s induce a
signature TME characterized by strong upregulation of IFNγ and
type I-associated chemokine receptors (CXCR6, CCR5, CXCR3,
and CCR1) to recruit tumor invading Rorcfm+ILCs in a mouse
model of melanoma (50). Adipose ILC1s were also found to
contribute to adipose tissue fibrogenesis in humans (51). Other
studies of ILC2s show that activation by IL-33 induces IL-
13 secretion, which in turn stimulates hepatic stellate cells to
produce ECM proteins leading to pathologic tissue remodeling
in mouse liver (52) (Figure 2). Depletion of RORγt-dependent
LTis and RORγt-independent ILCs impairs lung function and
tissue repair, whereas IL-33/IL-33R signaling is critical for lung
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FIGURE 2 | Innate lymphoid cells (ILCs) and extracellular matrix (ECM)
remodeling. Activated ILC interactions with ECM in tumor immune
microenvironment (TIME) conclusively affect the consequences of tumor
progression. Interferon-gamma (IFNγ) secreted by natural killer (NK) cells
stimulate tumor cells to express FN1 that causes ECM remodeling resulting in
the inhibition of tumor metastasis. Mutually, FN1 stabilizes NK cell survival and
facilitates NK cell migration through the induction of B-cell leukemia 2 (Bcl-2)
expression. In response to IL-12, ILC1s upregulate several cytokines and
chemokines, such as IFNγ, CXCR6, CCR5, CXCR3, and CCR1, to recruit
ILC3s to the tumor site, thus causing ECM remodeling and tumor growth
repression. Through ECM remodeling, adipose ILC1s contribute to adipose
tissue fibrogenesis. Similarly, in mouse liver, IL-33-activated ILC2s release
IL-13 to stimulate hepatic stellate cells to produce ECM proteins, thus
inducing liver fibrogenesis. Moreover, tumor cells recruit CCL21 to activate
LTis, whereby causing tumor stromal reorganization and facilitation of lymph
node metastasis.
ILC response through the production of AREG via IL-13/ IL-22-
independent mechanisms (53).
As described above, the remodeling of ECM causes organ
dysfunction and contributes to chronic disease mechanisms
including cancer. Innate immune cytokines derived from
ILCs subsets directly regulate fibroblast functions that are
independent of adaptive immunity (54). Taken together, these
studies demonstrate a critical role for ILCs as important
regulators of cytokine networks involved in ECM remodeling
and the consequences for health and disease. This also suggests
the clinical relevance of controlling pathologic remodeling to
prevent metastasis.
ILCs in Tumor Angiogenesis and Lymphatic
Vascular Networks
Tumoral angiogenesis is a characteristic feature of tumor
survival and progression, which differs considerably from the
vascular structure generated for the regular blood vessels
(55, 56). The formation of new blood vessels in tumors is
driven by hypoxic tumor cells, tumor-associated stromal cells
(TASCs), and the ECM in which they are embedded, producing
vascular endothelial growth factor A (VEGFA) to initiate tumor
angiogenesis (57). Tumor-infiltrating immune cells, such as ILCs,
are also important pro-angiogenic mediators to increase VEGFA
bio-availability and signaling during the angiogenic switch (58).
ILCs stimulate endothelial cell proliferation and upregulation
of adhesion molecules by releasing pro-angiogenic factors,
contributing to immune cell recruitment and perpetuation of
inflammation (42, 55, 56, 59).
Tumor-infiltrating NK cells, transformed from CD16+NK to
CD16−NK subset upon transforming growth factor-beta (TGF-
β) stimulation, predominate in non-small-cell lung carcinoma
(NSCLC) and produce elevated levels of pro-angiogenic factors
such as VEGF and placenta growth factor (PIGF) to sustain
tumor progression (55, 60, 61). This pro-angiogenic effect can be
reversed by transcriptional factor STAT5 via repressing VEGFA
transcription in NK cells, in both mice and humans (62). The
secretion of VEGF by NK cells is associated with angiogenesis
in human melanoma, and breast and colon carcinoma (42).
These studies suggest that the TIME is able to functionally
affect NK cells by inhibiting their cytotoxic ability or promoting
pro-angiogenic phenotypes by a wide array of cytokines and
soluble factors such as TGF-β, PGE2, VEGF, and adenosine (55).
Likewise, tumor-infiltrating ILC1s in mouse fibrosarcoma also
showed upregulation of angiogenesis gene sets that also expressed
in NK cells (63). ILC1s impaired tumor neovascularization
mediated by IL-12, which required the presence of NK cells
to induce endothelial cell cytotoxicity in lymphomas (64).
ILC1s produce two signature cytokines, IFNγ and TNFα, which
are associated with cell proliferation and angiogenesis. IFNγ
activates the transcription factor STAT1 to inhibit tumor cell
proliferation and angiogenesis (65, 66). TNFα can either destroy
tumor vasculature and induce apoptosis as an antitumor effector
or stimulate the expression of angiogenic and growth factors to
promote tumor formation and growth (38). ILC2s in response
to IL-33, the cytokine that induces angiogenesis and vascular
permeability through ST2 receptor binding (67), can enhance the
re-epithelialization and promote the restoration of skin integrity
after injury (68). ILC3s contribute to preserving epithelial
integrity and maintaining tissue homeostasis by the release of
IL-22 (59). Secretion of IL-17 by ILC3s promotes angiogenesis
via stimulation of vascular endothelial cell migration and cord
formation, resembling those indirect angiogenic stimulators
such as TGF-β and platelet-derived growth factor B subunit
homodimer (PDGF BB) in vivo (69). The indirect role of ILC3s
in tumor angiogenesis is also manifested by their recruitment
of myeloid-derived suppressor cells (MDSCs) and regulatory T
cell (Treg) cells, which in turn promote M2-like macrophages
in the TIME (70, 71). Apart from IL-17 and IL-22, the LTi-like
neuropilin (NRP)1+ILC3 subset was also found to release CSF2,
TNFα, B-cell-activating factor, and CXCL8, in association with
VEGF production that might contribute to angiogenesis (59)
(Figure 3).
The other prominent feature of tumor angiogenesis is the
expression of adhesion molecules such as vascular cell adhesion
molecule (VCAM) and intercellular adhesion molecule (ICAM),
which conveys the apparent tumor-immune privilege. In a
subcutaneous melanoma mouse model, NKp46+LTi cells alter
the tumor microvasculature upon IL-12 stimulation, which
leads to upregulation of VCAM and tumor suppression (72).
Indeed, LTis modulate not only blood vasculature but also
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FIGURE 3 | Innate lymphoid cells (ILCs) in tumor angiogenesis. ILCs act as
tumor angiogenesis modulators by releasing pro-angiogenic factors and by
inducing the recruitment and infiltration of immune cells to affect tumor-related
inflammation. Transforming growth factor-beta (TGF-β) secreted by tumor cells
activate natural killer (NK) cell to produce vascular endothelial growth factor
(VEGF) and placenta growth factor (PIG) to induce tumor angiogenesis;
conversely, the transcription factor STAT5 represses the expression of VEGF
resulting in the inhibition of angiogenesis and tumor growth. ILC1s produce
two signature cytokines, interferon-gamma (IFNγ) and tumor necrosis
factor-alpha (TNFα), that are associated with cell proliferation and
angiogenesis. TNFα secreted by ILC1s increases vascular cell adhesion
molecule (VCAM)1 expression causing tumor vascular formation, whereas in a
different context, TNFα-producing ILC1s can either destroy tumor vasculature
or induce apoptosis acting as antitumor effectors. Furthermore, IFNγ released
from ILC1s causes STAT1 activation, thereby inhibiting angiogenesis
formation. ILC2s respond to IL-33 and induce angiogenesis and vascular
permeability through ST2 receptor binding. IL-17 and IL-22 released by ILC3s
promote angiogenesis via stimulation of vascular endothelia cell migration and
cord formation. The indirect role of ILC3s in tumor angiogenesis is also shown
in the recruitment of myeloid-derived suppressor cells (MDSCs), regulatory T
cell (Treg) cells, and the promotion of M2-like macrophages in the tumor
immune microenvironment (TIME).
the lymphatic vascular system. LTis induce mesenchymal stem
cells (MSCs) to produce chemokines, CCL19, CCL21, or
CXCL13, which promote lymphocyte recruitment and spatial
compartmentalization (73). This cross talk also plays a role in
promoting lymph node metastasis in breast cancer. In the 4T1.2
triple-negative breast cancer (TNBC) mouse model, ILC3s are
recruited to the primary tumors by CCL21 and stimulate tumor
stromal cells to release CXCL13, leading to enhanced tumor cell
motility, lymphangiogenesis, and lymph node invasion by tumor
cells (74). These data suggest that the number of infiltrating ILCs
within the primary breast tumors could be used as a predictor of
metastatic and malignancy potential (74).
Tumor angiogenesis and lymphatic vascular formation
prompt tumor invasion and metastasis, the landmark events that
transform a locally growing tumor into a systemic metastatic
and life-threatening disease. As tumor-infiltrating ILCs can
polarize the TME to either protumor or antitumor effects by
the modulation of angiogenic activities and lymphatic vascular
networks, these cells represent valid targets for antitumor
immunotherapy and cancer preventive strategies (55).
Interplay Between ILCs and Cytokines,
Chemokines and Growth Factors in Tumor
Immune Microenvironment
Initiation of ILC response relies on sensing the cytokines,
alarmins, and inflammatory mediators that are derived
from tissue sentinels such as myeloid cells, dendritic cells
(DCs) and macrophages, or epithelial cells to translate
environmental signals into a specific cytokine profile (75).
The complex, diverse and dynamic interplay with surrounding
environments amplifies ILC signaling and determines their
function. Tumor-infiltrating immune cells engage in an
extensive and dynamic interaction with TIME and shape the
TME, whereas tumor cells also induce an immunosuppressive
microenvironment by the secretion of the cytokines and other
soluble factors (33).
In a model of subcutaneous melanoma, ILC1s respond to IL-
12, produced by tissue sentinels such as DCs and macrophages,
and alter the TME at an early stage of tumor development to
facilitate tumor suppression by infiltrating immune cells (72).
The production of TGF-β in the TME drives ILC fate outcomes
between the ILC subsets from NCR−ILC3s to NCR+ILC3s (76).
In human ovarian cancer, IL-22-producing ILC3s prevent tumor-
infiltrating lymphocyte activation and proliferation (27), whereas
the release of IL-22 and IL-17 by ILC3s modulates intestinal
immune pathology (77). In a preclinical mouse model of human
breast cancer, RORγt+ILC3 promoted lymphatic metastasis by
modulating the local chemokine milieu in the TME (74). Genetic
mapping of the fate of ILC3 revealed that different subsets of
ILC3 are phenotypically adapted to the local tissue environment
they invade, indicating that the function of ILCs is shaped not
only during their lineage commitment but also by the TME
(50). Although ILCs are characterized by the distinct signature
cytokine they express, tissue-derived cytokines can extrinsically
shape ILC function (50), and this cross talk can drive both
positive and negative consequences in tumor progression (78).
Interestingly, exosomes (extracellular vesicles, 50–150 nm in
size released from the endocytic compartment) (79) derived from
both tumors and stromal cells have been implicated as signaling
mediators between cancer cells and surrounding cells that
comprise the TME and contribute to therapy resistance. Several
studies have identified the role of exosomes in premetastatic
niche establishment that is favorable for future dissemination and
metastatic seeding through the communication with immune
cells like NK cells, macrophages, B cells, and T cells. Recent
studies also revealed that chemotherapy-elicited extracellular
vesicles in breast cancer cells can promote premetastatic niche
formation in lung by delivering annexin 6 to induce CCL2,
which promotes monocyte activation (80). The direct correlation
of exosomes with ILCs has not been explored yet, although
AREG, which is produced by ILC2s, can be found in distinct
nanoparticles (DNPs), a subset of extracellular vesicles that
are smaller than 50 nm with a dot-shaped morphology (81).
Further investigation of ILCs and exosome communication
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would potentially allow the development of effective clinical
applications that may overcome the therapeutic resistance.
Interplay Between ILCs and Adaptive
Immunity
Emerging evidence indicates that ILCs play an important role
in coordinating tissue-specific adaptive immunity and act as
master regulators in homeostasis and diseases. Substantial studies
have demonstrated the direct communication between ILC2s and
ILC3s with the adaptive immune system, whereas with ILC1s, it
remains less well-investigated (21).
ILCs share several developmental and transcriptional
signatures with T-cell subsets but have additional and/or
unique, non-redundant functions in T-cell polarization and
effector functions by secretion of regulatory cytokines, antigen
presentation, or direct cellular interactions within complex
tissue microenvironments. ILC2s functionally resemble Th2
cells and play a critical role in the type II immune response.
ILC2-derived cytokine IL-13 stimulates tissue DC recruitment
to the draining lymph node for eliciting production of Th2
cell-attracting chemokine CCL17, causing the Th2 response
(82). The protumor activity of IL-13 is also involved in the
activation and differentiation of MDSCs by induction of
Treg cell expansion to establish an immune-suppressive TME
(83). These studies may indicate that the role of ILC2/IL-13
axis in the initiation of cancers is linked to extensive tissue
remodeling. During intestinal or lung inflammation, tissue-
specific IL-33 secretion upregulates OX40L expression on
ILC2s resulting in protective Th2 immunity and Treg cell
expansion, which could be related to the induction of a tolerant
microenvironment and inhibition of antitumor responses (84).
In addition, ILC2-derived AREG limits antitumor immunity by
stimulating Treg cell expansion, supporting the establishment of
an immune-suppressive TME (85). ILC2s have been suggested
as a key source of Th2 master regulator IL-4 (86), and the
previously unrecognized role of ILC2-derived IL-4 in Th2
differentiation may indicate the potential involvement of
ILC2/T-cell interactions in promoting tumor growth and
metastasis (38). Notwithstanding the protumor role of ILC2s
in cancer, ILC2-derived cytokines such as IL-5 are involved in
an antitumor function. In a melanoma model, increased IL-5
production by ILC2 resulted in the recruitment and activation
of eosinophils, which was correlated with lung tumor metastasis.
Moreover, ILC2-derived IL-9 has recently gained attention in
the context of tumor biology and has functional importance as
growth factor for ILC2 and survival factor for other cell types
(83). In a melanoma model, IL-9 deficiency promoted tumor
growth, whereas IL-9 treatment decreased metastasis (87). It
is possible that the role of IL-9 in cancer is associated with
the promotion of infiltrating DC antigen presentation (88).
Conversely, high expression of IL-9 was associated with T-cell
transformation in humans, indicating that the anti-apoptotic
properties on transformed cells promote tumorigenesis (89)
(Figure 4).
Increasing evidence over the past decade also indicated the
role of ILC3s in bridging innate and adaptive immune responses.
In a bone marrow chimeric mouse model, RORγt+ILCs (LTis)
express OX40L and CD30L to regulate memory CD4+ T-cell
survival but not that of CD8+ T cells in the homeostatic
state (90), whereas in normal intestines ILC3s limit T-
cell activation but decrease the regulatory effects under an
inflammatory microenvironment through MCH-II presentation
(91), indicating that the function of ILCs can be altered by
mutual interaction with the microenvironment. ILC3s localize
at the boundary between B-cell follicles and T-cell zone within
intestinal draining lymph nodes to regulate T follicular helper
cells (Tfh) responses and B-cell class switching via antigen
presentation (92). In contrast to peripheral lymph nodes, resident
ILC3s at mucosal draining lymph nodes express MHC-II and
contribute to a distinct microenvironment constraining CD4+
T-cell response to commensal bacteria in a contact-dependent
manner dependent on CCR7 (93). Commensal microbiota and
IL-1β stimulate the release of GM-CSF and IL-22 by ILC3
through MHC-II-dependent interactions to promote intestinal
Treg cell expansion (94, 95). In addition, IL-1β stimulation leads
to activation of peripheral ILC3s and consequently primes the
CD4+ T-cell immune response, whereas T cell-derived effector
cytokines also cross-regulate the ILC response. The cognate
interaction of ILC3 and CD4+ T cells is bidirectional, indicating
an unappreciated role of ILC3s in T cell-mediated immunity
(96). ILC3 also activates local and systemic inflammatory T
cells by increasing TNF-like ligand 1A (TL1A) and IL-1β
(82, 95). In the peritoneal B-cell compartment, RORγt+ILCs
produce soluble lymphotoxin α3 (sLTα3) and membrane-
bound lymphotoxin β (LTβ), both trimeric cytokines of the
TNF superfamily, resulting in T cell-dependent and T cell-
independent IgA production, respectively (97). Moreover, the
adherent microbiota stimulates ILC3 to secrete IL-22 that
triggers epithelial serum amyloid A protein (SAA) production
to promote local Th17 responses in a STAT3-dependent manner
(98) (Figure 4). The proliferative and anti-apoptotic capacities
of ILC3-derived IL-22 may support malignant transformation
in chronic inflammatory diseases. Those studies revealed the
potential function of ILC3s as antigen-presenting cells and
directly modulate adaptive immune responses. Even though ILCs
show striking similarities to T-cell subsets, the non-redundant
functions go beyond those shared with T cells through indirect
and direct interaction with adaptive immune cells. In turn,
adaptative immunity reciprocally regulates ILCs, which indicates
that these bidirectional regulations are a crucial determinant
of immune response within tissues. Given that the abundant
evidence is mostly established under inflammatory conditions,
a functional analysis between ILC3s and adaptive immunity in
chronic inflammatory diseases may also imply the role of these
interactions in the malignant transformations.
Collectively, these studies demonstrate key innate
mechanisms in the regulation of the adaptive immune response
and shed light on the tissue ILC-mediated control of adaptive
immunity in orchestrating inflammatory and restorative tissue
responses (99). Delineating the complex network of ILCs with
other immune cells interactions will allow the manipulation of
their specific function and ultimately open a way to innovative
therapeutic strategies (41).
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FIGURE 4 | Innate lymphoid cells (ILCs) modulate adaptive immunity by direct or indirect interactions with other cells in the tissue. ILC2s functionally resemble Th2
cells and play a critical role in the type 2 immune response. The role of ILC2s in the establishment of an by direct interactions with Th2 cells through OX40L/OX40
under IL-33 stimulation or through indirect interactions by the section of IL-13 or amphiregulin (AREG), which then causes regulatory T cell (Treg) cell expansion and
myeloid-derived suppressor cell (MDSC) activation. ILC2-derived IL-13 also stimulates dendritic cell (DC) recruitment and CCL17 production to provoke a Th2
response. ILC2s produce IL-4 to regulate Th2 differentiation, which may suggest a potential role in promoting tumor growth and metastasis. In terms of antitumor
function, the release of IL-5 and IL-9 by ILC2s restrains tumor growth through eosinophils recruitment and activation and DC antigen presentation. Conversely, high
expression of IL-9 is associated with T-cell transformation in humans, indicating that the anti-apoptotic properties on transformed cells promote tumorigenesis. ILC3s
are important in the Th17 immune response. The direct interactions with CD4+T cells are either through MHC II/TCR or through OX40/OX40 and CD30L/CD30 to
regulate T-cell survival or B-cell class switch, respectively. ILC3 migrate to the draining mesenteric lymph node to initiate an adaptive response that requires CCR7
expression. ILC3s promote IgA production in a T cell-dependent manner via the regulation of CD4+T-cell homing by sLTα3 secretion and also in a T cell-independent
manner via control of B-cell homing by the release of LTα1β2. ILC3-derived IL-22 triggers epithelial serum amyloid A protein (SAA) production to induce local Th17
response in a STAT3-dependent manner. The secretion of IL-22 and GM-CSF by ILC3 stimulates macrophages and DCs to release IL-10, and this consequently
results in regulatory T cell (Treg) cell expansion. In addition, IL-1β produced by macrophages activates ILC3 and leads to CD4+T-cell priming, whereas T cell-derived
cytokines also cross-regulate ILC response, indicating the bidirectional interactions between ILC3 and T cell-mediated immunity.
INNATE LYMPHOID CELLS AND
CANCER-RELATED INFLAMMATION
Inflammation is a well-known hallmark of cancer that sustains
cancer progression by providing growth factors, proangiogenic
factors, and ECMmodifying enzymes. During the different stages
of tumor development, the inflammatory response plays decisive
roles in tumor initiation, promotion, malignant conversion,
invasion, and metastasis (100). Inflammatory conditions can
be present before or after a malignant change occurs, which
induces an inflammatory microenvironment to promote tumor
development (101). Cancer-related inflammation in the presence
of inflammatory cells and their mediators, such as cytokines,
chemokines and prostaglandins, in tumor tissue is similar to
that observed in a chronic inflammatory response (101). The
character of the inflammatory response and the composition
of the immune cell infiltration are indispensable to shape the
TIME (33).
ILCs are believed to be resident, whereas NK cells recirculate.
Given their distribution throughout the body, ILCs play a
critical role in coordinating inflammation and cancer (75).
ILC1s are highly abundant in the small intestine, liver, uterus,
and salivary glands; ILC2s are enriched in the skin and
lung; and ILC3s are abundant in the colon and tonsils (27,
102). Mucosal ILC1s are important in barrier defense through
escalating Th1-like responses against pathogenic infections (99).
During inflammation, a higher frequency of IFNγ-producing
ILC1 subsets in mucosal tissue is positively correlated with
patients having Crohn’s disease compared with the normal tissue,
indicating a role for ILC1 in the pathogenesis of gut mucosal
inflammation (103). ILC2s secrete the type 2 cytokines IL-5 and
IL-13 to control helminths, restrain parasitic infections (99), and
drive airway hyper-reactivity in mouse models of allergic asthma
(103, 104). Tissue-derived cytokines can also shape ILC function
in inflammation, and this is largely achieved by the IL-22 pathway
(78). In response to IL-23 stimulation, IL-22-producing ILC3s
facilitate tissue protection from the acute phase of Citrobacter
rodentium-induced colitis (105). ILC3-dependent protection
also occurs at other mucosal sites, including the lung and
oropharyngeal barrier through IL-17 and IL-22 (106–108). ILCs
are important in tissue repair and remodeling after infection.
IL-22+ILC3s limit inflammatory colitis, and their frequency
correlates with mucosal repair in inflammatory bowel disease
(IBD) (99). LTis are involved in tissue repair after clearance of
lymphocytic choriomeningitis virus infection (109), and ILC2s
assist lung tissue repair after influenza virus infection (53).
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Indeed, ILCs act as a two-edged sword in inflammation. The
same factors that inhibit acute inflammation and promote tissue
repair can have pathogenic effects during chronic inflammation
activation. IL-5-producing ILC2s boost lung inflammation by
recruiting eosinophils that are themain allergic effectors, whereas
maintenance of IL-13 production stimulates collagen deposition
leading to chronic fibrotic tissue damage and pulmonary fibrosis
in hyper-reactive lung airways (110–112). In the colon, chronic
infection-induced IL-23 triggers RORγt+ILC accumulation and
increases IL-17 and IFNγ production that results in the bacteria-
driven colitis (77). Furthermore, the protumor activities of
ILC3 are mainly associated with chronic inflammation by
IL-23-induced secretion of IL-17 and IL-22 (113). Antigen-
presenting ILC3s act as a checkpoint to control Tfh and
B cells response toward mucosal-dwelling microbiota (92).
Interestingly, regulatory ILCs (ILCregs) are found in both human
and mouse to protect intestines from inflammation through
inhibition of ILC1 and ILC3 activation regulated by IL-10
secretion (114).
ILCs as mediators of inflammation in various organs play a
key role in tissue remodeling and repair after recruitment and
activation, which are controlled by cytokines and growth factors
that are selective for each ILC member. Hence, targeting the
regulation of the tissue-specific response of ILCs in inflammation
may be beneficial in the setting of inflammation-driven cancer.
INNATE LYMPHOID CELLS IN PROTUMOR
AND ANTITUMOR EFFECTS
The role of ILCs in cancer is ambivalent as a double-edged sword
by engaging in cancer immune surveillance or enhancing the
unique tumor-promoting milieu, depending on the conceptual
framework. We review here the different subsets of ILCs in both
antitumor and protumor activities in the diverse contexts of
cancer (Table 1).
ILC1s
ILC1s are defined by the expression of T-bet and the production
of the signature cytokine IFNγ. The prototypical member of
ILC1s is the NK cell. NK cells recirculate and show strong
cytotoxicity, whereas ILC1s are tissue resident and only exhibit
weak cytotoxicity but produce more IFNγ and GM-CSF (131)
than NK cells do (26). ILC1s in response to IL-12, a potent
antitumor cytokine (115), produce the effector cytokines, IFNγ
and TNFα, to limit tumor growth in a melanoma mouse model
(132). The antitumor properties of ILC1s also depend on IL-15.
The expanded ILC1s in mouse mammary pre-cancerous lesions
exhibit potent cytotoxicity to limit tumor growth in response to
IL-15 (116).
However, ILC1s also show a more complex behavior and
display a detrimental role in cancer. Alteration of ILC subsets
composition in patients with acute myeloid leukemia (AML),
compared with the controls, could change the protective function
of ILC1s by increasing their frequencies and reducing IFNγ and
TNFα (118). Conversely, even though IFNγ is currently used as
a clinical target for treatment of malignancies, enhanced IFNγ
production by ILC1s is not associated with a better immune
response but shows an immunosuppressive effect in the presence
of IL-12-producing chronic lymphocytic leukemia (CLL) cells
(117, 124). Moreover, ILC1s are highly abundant in colorectal
cancer and produce IFNγ in response to IL-15 and IL-18, thus
inducing an immunosuppressive environment (102, 133). These
data suggest a dark side of IFNγ in tumor-promoting effects in
cancer, and further investigation might help to understand the
complex mechanisms of cancer progression in different contexts.
ILC2s
As an alarmin, IL-33 is released from nuclei to the extracellular
milieu upon cell injury caused by cell stress or damage and
activates ILC2s to initiate a type 2 immune response (120). IL-
33-dependent tumor-infiltrating ILC2s mobilize from lung and
recruit DCs to promote the adaptive T-cell response (119). ILC2
antitumor activity under IL-33 stimulation is also involved in
recruiting eosinophils to limit tumor growth and in shaping
chemokine profiles in the TME under IL-5 release (134). IL-33
promotes ILC2 secretion of CXCR2 ligands that bind to CXCR2-
expressing tumor cells, reinforcing tumor cell-specific apoptosis
independent of adaptive immunity (135). Secretion of IL-13 by
ILC2s activates CD8+ T cells through DC recruitment (120). In
addition, ILC2s are major sources of IL-9, which can decrease
tumor metastasis in a mouse model of melanoma (87).
Conversely, IL-13-producing ILC2s also show protumor
immunity and are associated with a negative outcome in cancer.
The ILC2/IL-13 axis modulates T cell-to-MDSC balance to
drive an immunosuppressive microenvironment, whereas the
inhibition of ILC2/IL-13 axis improves bladder cancer treatment
(125). Similarly, the IL-33/ILC2 axis also accelerates tumor
growth and promotes lung and liver metastasis by recruiting
MDSCs to produce IL-13 in a mouse model of breast cancer
(136), acute promyelocytic leukemia (APL), and prostate cancer
(123). ILC2s impair IL-33-mediated tumor suppression by
antagonizing the NK cell function during tumor growth via
CD73 independently of adaptive immunity in a melanoma
mouse model (119). Indeed, ILC2-derived IL-33 promotes tumor
formation and metastasis in breast cancer by upregulating
Treg cells through inducible co-stimulator (ICOS)/ICOS ligand
(ICOSL) interaction (121), whereas IL-33 also activates ILC2s to
recruit eosinophils through ICOS/ICOSL interaction during lung
inflammation (137). Moreover, ILC2-derived AREG expression
favors lung tumor growth and enhances resistance to apoptosis
(126). Increased numbers of ILC2s were found in inflamed
colonic tissue of patients with ulcerative colitis, a condition
associated with a high risk for development of inflammation-
driven colorectal cancer (122). Clinical studies have shown
that ILC2s and their cytokines (IL-33 and IL-4) accumulate
in peripheral blood and contribute to immune-suppressive
environment formation in gastric cancer patients (138). The
mediation of resistance to apoptosis indicates a poor prognosis
in a number of cancers (139, 140).
All these data indicate that the function of ILC2s and their
related cytokines are cell context dependent to facilitate either
protumor or antitumor activities.
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TABLE 1 | ILCs in different cancer types with anti-/pro-turmeric effects.
Cancer types Functions (anti-/pro-tumor) References
ILC1s Melanoma Anti-tumor: ILC1s in response to IL-12, produce IFNγ and TFNα to limit tumor growth. (115)
Colorectal Cancer Anti-tumor: intraepithelial CD127− ILC1s (ieILC1) produce cytotoxic granules to repress tumor growth. (102)
Mammary pre-lesion Anti-tumor: ILC1s number expansion exhibits potent cytotoxicity to limit tumor growth in response to IL-15. (116)
CLL Pro-tumor: CLL cells induce ILC1s produce IFNγ and TNFα and form immunosuppressive environment. (117)
AML Pro-tumor: reduce IFNγ and TNFα production. (118)
ILC2s Melanoma Anti-tumor: IL-9-producing ILC2s inhibit tumor metastasis in mouse melanoma model. (87)
Lymphoma Anti-tumor: IL-33 stimulates ILC2s to secrete CXCR2 ligands that bind to CXCR2-expressing tumor cells to
induce tumor cell-specific apoptosis independently of adaptive immunity.
(119)
Lung cancer Anti-tumor: IL-33 dependent tumor-infiltrating ILC2s mobilize from lung and facilitate dendritic cells to promote
adaptive T cell response.
Pro-tumor: IL-33 actives ILC2s to recruit eosinophils through ICOS/ICOSL interaction.
(120)
(121)
Colorectal cancer Pro-tumor: Increased ILC2 are associated with high risk for development of inflammation-related CRC. (122)
Breast cancer Pro-tumor: IL-33/ILC2 axis facilitates tumor growth and metastasis by recruiting MDSCs to produce IL-13.
Pro-tumor: ILC2s promote breast cancer growth by upregulating Tregs through ICOS/ICOSL interaction.
(123)
(124)
Bladder cancer Pro-tumor: ILC2/IL-13 axis modulate T cell–to-MDSC balance driving an immunosuppressive TME. (125)
Gastric cancer Pro-tumor: Accumulation of ILC2s and their cytokines, IL-33 and IL-4 contribute to immune-suppressive
environment.
(126)
Prostate cancer Pro-tumor: ILC2 elevated tumor-derived PGD2 and B7H6 and activated MDSCs via IL-13 secretion to promote
tumor growth.
(123)
APL Pro-tumor: ILC2 elevate tumor-derived PGD2 and B7H6 to active MDSCs via IL-13 thus inducing
immunosuppressive effects.
(123)
ILC3s Melanoma Anti-tumor: IL-12 promotes NKp46+CD49b−RORγt+ ILC3 expansion and upregulation of VCAM1 to facilitate
immune leukocyte infiltration resulting in tumor suppression.
(72)
Lung (NSCLC) Anti-tumor: NCR+ ILC3s produce IL-22, TNFα, IL-8 and IL-2 to activate endothelial cells forming protective
tumor-associated tertiary lymphoid structures.
(127)
Colorectal cancer Pro-tumor: ILC3s sustain colon cancer via production of IL-22. (128)
Breast cancer Pro-tumor: CCL21-mediated recruitment of ILC3 triggers CXCL13 secretion by TME stromal cells thereby
enhancing tumor cell motility and promoting lymph node metastasis.
(74)
Hepatocellular
carcinoma
Pro-tumor: NCR− ILC3s initiate IL-17 production upon IL-23 stimulation and promote hepatocellur carcinoma
development.
(129)
Cervical carcinoma Pro-tumor: IL-17-producing ILC3s are also associated with poor survival in early stages. (130)
ILC3s
Same as the other ILC subsets, ILC3s are also associated with both
antitumor and protumor activities. NCR+ILC3 concentrates
in human NSCLC and associates with intratumoral lymphoid
structures, which contribute to the formation of an antitumor
environment and act as predictors of favorable clinical outcome
(127). In a mouse model of melanoma, increased IL-12
promotes NKp46+CD49b−RORγt+ILC3 expansion leading to
upregulation of VCAM1 to facilitate leukocyte infiltration and
the mediation of tumor suppression (72).
Conversely, ILC3s can be associated with tumor growth
under different contexts. In a mouse model of colorectal
cancer, NCR+IL-22+ILC3s, previously known as NK22 cells
that are phenotypically distinct from LTis, sustain colon
carcinogenesis in chronic inflammation (141). IL-22-producing
ILC3s are crucial for the IL-22-mediated innate immune
response. Notably, other subsets of ILC3s can also produce IL-
22 such as CD4+ILC3s, which lack NCR expression in the gut
(142). NCR−ILC3s promote hepatocellular carcinoma (HCC)
development in response to IL-23 to produce IL-17, which
directly limits CD8+ T-cell immunity by enhancing lymphocyte
apoptosis and inhibiting their proliferation (129). By using an
immunodeficient Rag−/− mouse model, it has been shown
that NKp46−CD4−ILC3 accumulation leads to IL-17 and IL-
22 production, which promotes tumor development, whereas
depletion of ILCs with anti-Thy1 mAbs limits tumor growth in
colon cancer (141). Similarly, RORγt+ILC3s are associated with
an increased incidence of metastasis in human breast cancer,
as it was shown that depletion of ILC3 using an anti-CD90.2
antibody reduced tumor cells metastasis to lymph nodes in a
syngeneic 4T1.2 mouse model (74). IL-17-producing ILC3s are
also associated with poor survival in early stages of squamous
cervical carcinoma (130). Interestingly, one study showed that
a previously uncharacterized ILC population, ILCregs, can
produce IL-22 and exhibit low cytotoxicity with a gene expression
profile that overlaps with NK cells and other ILCs showing
the same immunosuppressive capacity as Treg cells in human
ovarian cancer studies (39).
Nevertheless, emerging evidence indicates the balance of
power of ILCs in the context of cancer, and many ILC functions
appear to be regulated by mechanisms distinct from those of
other innate and adaptive immune cells. Notably, many studies
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of ILCs in cancer are based on the Rag-deficient mouse models
lacking adaptive immunity. Although these experiments were
crucial to analyze the fundamental features of ILC biology, these
approaches have hampered the ability to study ILCs in the context
of adaptive immunity and the potential interplay between ILCs
and adaptive lymphocytes. The challenge now is to understand
their roles and contribution within a complete immune system.
The extent to which ILCs regulate the immune response (with
antitumor or protumor activities) in a multitude of contexts need
to be further analyzed. This is important for the understanding
of their roles in cancer and for identifying targets for use in
clinical treatments. In summary, although current studies reveal
an important role of ILCs during tumor development, their
indistinct functions in humans are incompletely understood.
INNATE LYMPHOID CELL
HETEROGENEITY AND PLASTICITY
The pleiotropic roles of ILCs in cancer are dictated by their
heterogeneity and plasticity, the noteworthy capacity of ILC
subsets to convert into one another. Like helper T cells, the
function and phenotype of ILCs can be modulated by extrinsic
signals. In the context of cancer, mature ILCs exhibit substantial
plasticity depending on the distinct cytokines present in the
microenvironment milieus (143) (Figure 5).
NK Cells to ILC1s and ILC3s
In a mouse model of fibrosarcoma and melanoma, TGF-β in
the TME induced mouse NK cells to convert into non-cytotoxic
ILC1s, thus weakening the control over tumor growth and
metastasis (63, 144, 145). Recent studies revealed that NK cells
can permanently transform to Eomes−T-bet-dependent ILC1-
like cells independently of ongoing infection, which may explain
the discrepancies of ILC1-like cells with either having antitumor
function or as an inflammatory subpopulation. This exemplifies
the current limitations of NK cells and ILC categorization on the
basis of only their phenotypes as discrete ILC lineages (146). NK
cells can also be converted into ILC3s. IL-1β stimulation prevents
stage 3 NK cells from differentiating into stage 4 mature NK cells,
thus keeping an ILC3-like phenotype with IL-22 production and
IL-1R1 expression (147).
ILC1s to NK Cells, ILC2s, and ILC3s
In TGF-β knock-out mice, the ILC1 number decreased in
salivary glands concurrent with increased expression of CD49a,
CD103, and CD69, suggesting the potential for ILC1 to NK
cell plasticity (148). IL-4 accumulation leads to a shift from
ILC1s toward ILC2s, which can be reversed by IL-12, in patients
with severe chronic obstructive pulmonary disease (COPD) or
chronic rhinosinusitis with nasal polyps, suggesting the induction
of IL-12 and IL-4 signatures in ILC1s and ILC2s, respectively
(149). Differentiation of ILC1s to ILC3s is driven by IL-23 (103),
and this can be enhanced by IL-1β and retinoic acid produced
by CD14−DC (103, 149, 150). The enhanced accumulation
of ILC3s likely promotes tumorigenesis within different tissue
locations (151).
ILC2s to ILC1s and ILC3s
Conversion of ILC2s into ILC1s has been shown in the intestines
of patients with Crohn’s disease (152) and in the lungs of patients
with COPD (25). Inflammation may increase ILC plasticity,
thereby increasing the risk of cancer development. IL-1β also
converts ILC2s into ILC1s, resulting in the increase of T-bet and
IL-12Rβ2 expression, which promotes ILC1s in response to IL-12
(153). Mouse lung inflammatory ILC2s, in response to IL-25, can
differentiate into IL-17-producing ILC3s that play an important
role in antihelminths and antifungal immunity (154).
ILC3s to NK Cells, ILC1s, and ILC2s
Human ILC3s treated with IL-15 and IL-12 initiate the expression
of NK cell cytotoxicity markers (Eomes, CD94, CD56 NKG2A,
and NKG2C), suggesting a beneficial role for ILC3-NK plasticity
in cancer (155, 156). Plasticity between ILC3 and ILC1 mediated
by IL-23 and also IL-12 produced by CD14+DC promotes
polarization from ILC3s toward ILC1s, which ultimately affects
tumor immunosurveillance in response to various environmental
changes (2, 103, 150). IL-23-induced activation of STAT4 in
NCR+ILC3s is a key determinant of plasticity from NCR+ILC3s
toward ILC1s, as demonstrated by a transcriptomic analysis
(157). Moreover, ILC3-to-ILC1 transition was tissue dependent
and relied on transcription factor Aiolos and T-bet cooperation
to repress regulatory elements active in ILC3s. This highlights the
relevance of the tissue niche in creating a microenvironment that
promotes ILC diversity and functional adaptation to local stimuli
(158). ILC3s convert into ILC2s after activation with IL-2/TLR2
signals. In humans, IL-23 stimulation induces IL-22 secretion
by ILC3s, which display clonal heterogeneity for IL-13 and IL-5
production indicating polarization in vivo (159).
NCR−ILC3s to NCR+ILC3s
Mouse NCR−ILC3s that differentiate into NCR+ILC3s need
Notch signals; conversely, TGF-β can convert NCR+ILC3s into
NCR−ILC3s, indicating that bidirectional plasticity of ILC3s is
regulated by the balance between the opposing effects of Notch
and TGF-β signaling in the face of challenges (76).
Interestingly, genetic evidence shows that the differences in
specific chromatin regions such as cis-acting enhancers and
silencers that bind to transcription factors may determine the
apparent plasticity of ILCs compared with the T-helper subsets.
With the use of ATAC-sequencing to evaluate chromatin regions
accessibility, the regulatory regions that control the distinct
cytokine gene expression in ILCs exhibit poised or active status,
whereas the identical regions in CD4T helper cell counterparts
become accessible only after stimulation (160, 161). These results
indicate that ILC regulomes are prone to dynamic changes, and
the resilient feature of ILCs directly affects their plasticity in
response to the TME.
As discussed above, ILC plasticity, the ability to modify their
functional phenotypes, is a fundamental phenomenon that can
contribute to tumor escape mechanisms by altering the ILC-
dependent tumor-surveillance system. Fully understanding the
ILC plasticity controlmechanisms is essential formanipulation of
ILC function in the TME and designing novel therapeutic targets
to prevent tumor metastasis.
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FIGURE 5 | The plasticity between innate lymphoid cell (ILC) subsets. Mature ILCs display substantial plasticity depending on the distinct cytokines, the
microenvironment milieus, and the diverse context of cancer. Natural killer (NK) cells convert into non-cytotoxic ILC1s upon transforming growth factor-beta (TGF-β)
stimulation in the tumor microenvironment (TME) in mouse fibrosarcoma and melanoma. NK cells also convert into ILC3s in response to IL-1β, preventing stage 3 NK
cells from stage 4 mature NK cells and retaining ILC3-like phenotype. ILC1s show plasticity toward all other ILCs subtypes, including NK cells, ILC2s, and ILC3s with
the absence of TGF-β, the accumulation of IL-4, and under the stimulation of IL-23, respectively. Conversion of ILC2s to ILC1s needs IL-1β, whereas ILC2s in
response to IL-25 differentiate into IL-17-producing ILC3s. ILC3 treatment with IL-15 and IL-12 leads to NK cell conversion, whereas plasticity from ILC3s toward
ILC1s and ILC2s depends on IL-23, IL-12, and IL-2/TLR2 signals. NCR− ILC3 and NCR+ ILC3 conversion needs Notch and TGF-β signals, indicating the bidirectional
plasticity of ILC3s in the face of different challenges.
TARGETING INNATE LYMPHOID CELLS
FOR CANCER IMMUNOTHERAPY
Over the last two decades, cancer treatment has been
revolutionized from targeting the tumor itself with traditional
methods like surgery, chemotherapy, and radiotherapy to
boosting the immune system coordinating with TIME to control
cancers. Diverse approaches of immunotherapy including
targeting cytokines, immune checkpoint blockade (ICB), and
administration of depleting or agonistic antibodies have been
used to enhance antitumor activities (27).
ILCs were first identified at the mucosal barriers, but more
recent data confirm that ILCs exist in most, if not all, tissue types
(75). ILCs are among the first immune cells to react to changes
in environmental signaling and to shape TIME to coordinate
the adaptive immune response, providing promising targets for
cancer immunotherapy strategies.
Targeting Cytokines
As immunomodulators, ILCs produce their signature cytokines
and respond to various cytokines produced from other cell
types and the surrounding environments. Cytokine-based
immunotherapies such as IL-2 family, IL-10, IL-12, TGF-β, and
several other immunosuppressive cytokines are currently under
ongoing clinical trials for cancer treatment (30, 162, 163). IL-
2 is a key cytokine in promoting the expansion of cytotoxic
lymphocytes. IL-2 receptors, CD25, and CD122 are expressed
on mouse ILC2s, whereas human ILC2s and ILC3s show high
expression of CD25 only. In response to IL-2 stimulation, ILCs
can be expanded and activated to facilitate antitumor effects
(128, 164). However, the systemic administration of this cytokine
frequently causes grade 3 and 4 adverse effects owing to its
toxic profile even at the recommended doses. Several second-
generation IL-2-based compounds have been engineered to
reduce the high-affinity binding to IL-2Rα/CD25 and increase
the half-life in circulation (163). Directed conjugation of
polyethylene glycol (PEGylation) generates an inactive cytokine
with a long half-life in circulation. PEGylated IL-2 (NKTR-
214) has been shown to preferentially activate CD122, and this
modified cytokine is currently being evaluated in phase I/II
clinical trials for the treatment of various tumors (27, 165). IL-15
and IL-15 super-agonist ALT803 exhibit capabilities to increase
NK cell cytotoxicity in AML patients (166) and other tumor
models such as advanced solid tumors (NCT01946789), multiple
myeloma (NCT02099539), relapsed hematologic malignancy
(NCT01885897) (27) and metastatic NSCLC (NCT02989844)
(167). IL-10 is released by innate and adaptive immune cells
to regulate pro-inflammatory cytokines activity. IL-10 exhibits
a context-dependent outcome in cancer, and administration
of PEGylated IL-10 increases its half-life to avoid grade 3–4
immune-related adverse effects. This feature has been evaluated
in a phase I clinical trial in advanced, treatment-refractory
tumors (NTC02009449) (163). The antitumor and protumor
effects of TGF-β in cancer are based on the control of epithelial
cell growth and promoting epithelial–mesenchymal transition
(EMT), respectively. Although their efficacy as monotherapy
agents is limited, combined blockade of TGF-β using small
molecules or antagonistic monoclonal antibodies with immune
checkpoint inhibitors such as PD-1/PD-L1 (NCT02423343 and
NCT02734160) shows great potential for blocking the functions
of this cytokine (163). TGF-β receptor type 1 (TGFBR1)
inhibitors are currently used in phase I clinical trials to treat
advanced solid tumors (NCT02160106) or in combination
with pomalidomide for multiple myeloma (NCT03143985) (30).
Because of the intimate links between cancer and inflammation,
future cancer immunotherapies may benefit from repurposing of
anti-inflammatory treatments that are already in human trials
for chronic inflammatory diseases such as IBD. For instance,
anti-IL-12 and IL-23 blocking antibody ustekinumab has been
approved for clinical trials in Crohn’s disease (168). Targeting
Frontiers in Immunology | www.frontiersin.org 11 February 2020 | Volume 10 | Article 3111
An et al. Pleiotropic Role of ILCs in Cancer
IL-17 or IFN-γ alone failed to show any effects in clinical
trials, whereas targeting both provided favorable results in a
preclinical model on IBD (77). Antibodies against IL-5 and anti-
IL-4 receptor α subunit that block ILC2 function have provided
encouraging results in patients with chronic rhinosinusitis
(169). Similarly, inhibition of ILC2 function by chemoattractant
receptor-homologous molecule expressed on Th2 cells (CTTH2)
antagonists restores lung function in patients with asthma (170).
Cytokines are complex immune mediators with great
potential in clinical cancer immunotherapy. The safety and
effective use of cytokine-based drugs require a thorough
knowledge of cytokine biology and advanced biotechnology in
order to exploit their antitumor activity while minimizing their
toxicity. In a combination with other immunomodulatory drugs
such as immune checkpoint inhibitors and chimeric antigen
receptor T cells, cytokine immunotherapy might become a more
effective strategy in cancer treatment.
Immune Checkpoint Blockade
ILCs share some activating and inhibitory receptors with NK
and T cells, suggesting potential targets for immunotherapeutic
applications. ICB is an emerging antibody-based immunotherapy
providing promising strategies for cancer treatment. Antibodies
targeting immune checkpoints including CTLA-4, PD-1, and
PD-L1 have now been approved and used in the clinics for
diverse cancer treatments (171, 172). Activation of mouse ILCs
shows upregulation of PD-1, whereas increased PD-1 expression
on ILC2s and ILC3 has been found in human gastrointestinal
tumors, and highly expressed PD-1 and CTLA-4 were shown
in human breast cancer (133, 173). Strikingly, only a minority
of treated patients have benefited from of PD-1 blockade, with
some others displaying drug resistance. Therefore, understanding
how to shape the TME in order to increase the sensitivity to PD-
1 blockade becomes indispensable. The preclinical and clinical
studies in TNBC have shown that low-dose chemotherapy with
doxorubicin or cisplatin or irradiation induces a favorable TME
that increases the sensitivity to nivolumab treatment for PD-1
blockade to stimulate an anticancer immune response (174).
Another immune checkpoint activation protein, inducible
co-stimulator (ICOS) expressed on CD4+T cells as well as
on ILC2s and ILC3s, was identified as a crucial player in
CTLA-4 blockade antitumor effects. Engagement of the ICOS
pathway markedly enhances the efficacy of CTLA-4 blockade
in cancer immunotherapy in a mouse model of melanoma
and prostate cancer (175). Currently, an anti-ICOS agonist
antibody (GSK3359609) is being used in a phase I clinical trial
aimed at patients with solid tumors. In addition, therapeutic
antibodies against other immune checkpoints have also been
developed, such as TIM-3, LAG-3 (expressed on ILC1s only),
and TIGIT (expressed on both ILC1 and ILC3s) (176). Moreover,
monalizumab, an antibody against NK cell checkpoint protein
NKG2A, showed the capability to enhance antitumor immunity
by promoting both NK and CD8+ T-cell function. Based on these
findings, monalizumab in combination with cetuximab is being
used in head and neck squamous cell carcinoma phase II clinical
trial (177).
Depleting or Agonistic Antibody
Application and Others
Both experimental mouse models and human samples showed
that therapeutic targeting of ILC3 could be beneficial for
autoimmune diseases. For example, depletion of ILCs by
anti-Thy1 antibody improved the treatment for Helicobacter
hepaticus-induced colitis (77). In the context of nonsolid tumors,
human ILCs can be depleted before hematopoietic stem cell
transplantation to treat acute leukemia (178).
Adenosine signaling belongs to ametabolic pathway that plays
an important role in the immunosuppressive microenvironment
favorable for cancer development. ILC1s express CD39 and
CD73, activating the adenosine pathway in mouse salivary glands
and increasing an immunosuppressive TIME for tumor growth,
suggesting a potential target for therapeutic approaches (148).
So far, comprehensive information on the phenotypic and
functional characterization of ILCs has been gathered. After the
initial observation of the antitumor cytotoxicity of NK cells,
other ILCs have become attractive targets for immunotherapy
based on their abilities to rapidly sense and respond to signaling
changes in the TME. The current challenge in cancer biology is
to harness the cytokines, growth factors, and chemokines that
regulate the specific function of ILCs within the TME, and further
investigations will help to develop the exploitable targets for
clinical applications.
CONCLUSIONS AND PERSPECTIVES
Despite advances in immunotherapies for cancer treatment,
some patients still encounter few or no clinical benefits with the
same treatments. Given the unique, non-redundant roles of ILCs
within cancers, development of rational therapies that specifically
target ILCs is likely to boost the immunotherapeutic effects in a
larger group of cancer patients.
State-of-the-art technologies like single-cell RNA-sequencing
(173) and high-dimensional mass spectrometry (CyTOF)
analysis (179) have allowed us to investigate ILCPs, delineate
distinct ILCs subsets and their developmental pathways, and
identify novel mediators of antitumor immunity at single-cell
resolution levels. These studies present new perspectives for
exploring the complexity of ILCs in the diverse context of cancers
and allow effective manipulation of ILC immunosurveillance to
achieve optimal therapeutic opportunities.
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